Mark Anderson is the publisher of the SNS Global Report on Technology and the Economy (www.stratnews.com), read by Bill Gates, Elon Musk, Vint Cerf, Michael Dell, Paul Allen, Paul Jacobs, Craig Venter, Bill Janeway, Robert Hormats, Leroy Hood, Larry Smarr, and technology executives and investors worldwide. He is also the founder and chair of the Future in Review (FiRe) conference (www.futureinreview.com), named "the best technology conference in the world" by the Economist. Mr. Anderson's work includes the creation of SNS Project Inkwell (www.projectinkwell.org), the first global consortium to bring vendors, educators, and students together to accelerate the deployment of appropriate technology into K-12 schools; SNS Interactive News (www.snsinews.com), using patented processes to bring daily interactive communications worldwide, "About Leaders, For Leaders"; a new Global Rescue System for victims of human trafficking, in concert with Julia Ormond's ASSET program; Orca Relief Citizens' Alliance (www.orcarelief.org), the sole nonprofit organization working to reduce killer whale mortality rates; and Nutritional Microanalysis, a new field of medical research and practice aimed at connecting biochemical descriptions of food with health.
Sharon Anderson Morris
Sharon Anderson Morris is the programs director for Strategic News Service and SNS Future in Review (FiRe) events; the managing director of FiReFilms, supporting world-changing documentaries from conception through distribution to create positive global awareness and change; and Co-Founder and Interviewer for the annual Park City Institute / SNS "Future in Review" Speaker Series. Sharon is also on the Utah Lieutenant Governor's Technology Task Force as well as the Hyperloop Transportshion Technologies Team. After receiving her undergraduate degree in International Business and French Translation, Sharon went on to Celanese Chemical Corp. while studying for her master's degree in International Business. She became the firm's first female international salesperson for Asia, South America, Canada, and Australia/New Zealand before joining the Solvents Marketing Group.
Alan Beggs, Ph.D.
Dr. Alan Beggs is director of The Manton Center for Orphan Disease Research at Children's Hospital Boston and the Sir Edward and Lady Manton Professor of Pediatrics at Harvard Medical School. He received his AB in biology at Cornell University and his Ph.D. in human genetics at Johns Hopkins University. He then completed postdoctoral fellowships in medical genetics at Johns Hopkins University and in clinical molecular genetics at Harvard Medical School, and has directed an independent research laboratory in the Genetics Division at Children's Hospital since 1992.
Murray Cantor, Ph.D.
Dr. Murray Cantor has been leading cutting-edge ideas in software and systems development for over 35 years. Prior to his recent retirement from IBM as a Distinguished Engineer, he led the application of predictive analytics to software and systems planning and development and was the Rational Lead for Analytics and Optimization for Software and Systems. In addition to many articles, he is the author of two books, "Object-Oriented Project Management with UML" and "Software Leadership: A Guide to Successful Software Development." Dr. Cantor received his Ph.D. in Mathematics from the UC Berkeley.
Vik Chandra is the CEO of Muses Labs where he is creating solutions to make Precision Medicine practical and pervasive in the clinic. He has deep experience in business strategy, product management, business development, and technology development. His previous roles include business strategy leadership at large organizations such as IBM and leadership roles at startups such as neoButler Inc., which he co-founded and led the R&D team focused on personalization services. Mr. Chandra has a Masters in Computer Engineering from North Carolina State University and he holds three technology patents.
Florence Comite, MD
For over 20 years, Dr. Florence Comite has been a leader in the transformative field of Precision Medicine. A noted endocrinologist, Dr. Comite is a Yale Medical School graduate and former faculty member, the founder of Women’s Health at Yale, and a former fellow at the National Institutes of Health. At her practice in New York City, Dr. Comite employs a full arsenal of health technologies that includes genetics, metabolomics, proteomics, brain, body and bone diagnostics, hormones, biomarkers -- as well as the vital role of family history and lifestyle -- to detect, prevent, and reverse impending disease at the cellular level -- years, sometimes decades, before symptoms appear. Dr. Comite’s work as a Precisionist has been featured in the Wall Street Journal, Prevention Magazine and the New York Times. She has written and lectured extensively on the subject of Precision Medicine, including Op-Eds featured on CNBC.com, in Newsweek, and via a Letter to the Editor in the New York Times International Edition; interviews at Yahoo! Health and Becker’s Hospital Review; and media appearances on CNBC’s Closing Bell, Fox News with Neil Cavuto, and NBC New York. Her Amazon best-selling book for men, "Keep It Up: The Power of Precision Medicine to Conquer Low T and Revitalize Your Life," is the first book to be published for the mass market on the subject of Precision Medicine.
Corey DeHaven is the CEO of Essential3 Holdings, Inc. Essential3 is shaping the emerging field of wellness by creating an integrated, functional-medicine platform that includes patient care, clinical diagnostics and healthcare data analytics. He is formerly the head of informatics at Metabolon, Inc. where he was responsible for all software engineering, data management, and information systems within the organization. Corey was also a member of the Metabolon foundation team and provided the strategic vision for how metabolomics analysis can be stored, processed, and analyzed on an industrial scale. He has worked closely with scientists, statisticians, and clients to understand the challenges of driving meaningful and actionable results from the sizable scientific data streams and is credited with several issued patents and publications related to scientific computing.
DeAunne Denmark, MD, Ph.D.
Dr. DeAunne Denmark completed the Medical Scientist Training Program at Oregon Health & Science University (OHSU) in 2011 with a Ph.D. in Neuroscience and Behavioral Genetics. Supported by an NIH fellowship, her work focused on understanding genetic vulnerability to complex neuropsychiatric disease and involved precision medicine technologies including behavioral, genomics, protein biochemistry, and systems-based network bioinformatics. She serves as a Research Associate in systems neurogenetics at OHSU, Assistant Professor in Healthcare Design at Pacific Northwest College of Art, and as a consultant to Metabolon on the clinical translation of metabolomics, informed by her experience over the last four years as a patient with an undiagnosed illness. Four months after completing her M.D./Ph.D. training at OHSU, Dr. Denmark underwent a root canal while traveling in New Zealand. Three months later, she could hardly get out of bed. After a three-year diagnostic odyssey involving multiple specialists, procedures, and untargeted treatments, metabolomics is finally shedding some light.
Joel Dudley, Ph.D.
Dr. Joel Dudley is currently Assistant Professor of Genetics and Genomic Sciences and Director of Biomedical Informatics at Mount Sinai School of Medicine. Prior to Mount Sinai, he held positions as Co-founder and Director of Informatics at NuMedii, Inc. and Consulting Professor of Systems Medicine in the Department of Pediatrics at Stanford University School of Medicine, where he participated in leading research to incorporate genome sequencing into clinical practice (published in The Lancet, Cell, and PLoS Genetics). Dr. Dudley's current research is focused on solving key problems in genomics and precision medicine through the development and application of translational and biomedical informatics methodologies. His lab publishes in the areas of bioinformatics, genomic medicine, personal and clinical genomics, as well as drug and biomarker discovery. His recent work with co-authors describing a novel systems based approach for computational drug repositioning (published in Science Translational Medicine) was featured in the print edition of the Wall Street Journal and earned designation as the NHGRI Director's Genome Advance of the Month. He is co-author of the book "Exploring Personal Genomics" from Oxford University Press. He received a BS in Microbiology from Arizona State University and an MS and Ph.D. in Biomedical Informatics from Stanford University School of Medicine.
Mr. Ferguson is the Co-Chief Investment Officer for the Generation IM Global Equity Strategy. Generation Investment was established in April 2004 as an independent, private, investment management partnership. Generation's investment approach is based on our conviction that sustainability research integrated into a rigorous traditional investment process can deliver superior investment returns. Generation has built a global research platform to integrate sustainability research into fundamental financial analysis. We focus on key drivers of global change, including climate change and environmental degradation; poverty and development; water and natural resource scarcity; pandemics and healthcare, and demographics, migration and urbanisation. Generation's vision is to embed sustainability into the mainstream capital markets, and our core values reflect our commitment to responsible citizenship. A proportion of the Firm's profitability funds The Generation Foundation, which will support global non-profit sustainability initiatives.
Jennifer R. Friedman, MD
Dr. Jennifer Friedman is an expert in adult and pediatric movement disorders and has particular interest in genetic and metabolic disorders that affect movement. She directs the Movement Disorders and Tourette/Tic Disorder Clinics at Rady Children’s Hospital and does research in the areas of neurogenetics, Tourette’s Syndrome and disability awareness education. In addition, she teaches medical students residents, fellows, and undergraduate students. Dr. Friedman received her undergraduate training at Princeton University and earned her MD from Stanford University in 1991. She completed an internship in internal medicine at Santa Clara Valley Medical Center followed by residency in neurology at Harvard Longwood Training Program. She was a clinical fellow in movement disorders at Boston University Medical Center and a clinical and research fellow in neurogenetics and dystonia at Massachusetts General Hospital. She served as a neurologist at several Boston hospitals and was an instructor in neurology at Harvard Medical School before joining Rady Children’s Hospital in San Diego as senior staff neurologist in 2004. Dr. Friedman also serves as clinical professor in the UC San Diego Departments of Neurosciences and Pediatrics. Dr. Friedman is a diplomate of the American Board of Psychiatry and Neurology. She is a member of the American Academy of Neurology, the Movement Disorder Society, the Tourette Syndrome Association, and the Phi Beta Kappa National Honor Society.
Charles Goldstein, Ph.D.
Dr. Charles Goldstein holds a Ph.D., in Chemical and Biomolecular Engineering, from Princeton University and an MS, in Chemical Engineering, from the Johns Hopkins University. Currently, Dr. Goldstein is an advisor to large and medium companies seeking to diversify into Health Care and to start ups seeking to take new innovations to market. Prior to his retirement from Becton Dickinson in early 2016, Dr. Goldstein was a Sr Vice President most recently responsible for R&D in Asia. Prior to that Dr Goldstein led BD Technologies (BDT) responsible for all activities and operations in Research Triangle Park, North Carolina. Dr Goldstein championed and introduced new innovation initiatives and practices at BDT and across BD. Before leading BDT, Dr. Goldstein led R&D for BD’s Medical business. Over the course of his career many new products were introduced that now account of billions of dollars of annual sales. In addition Dr. Goldstein led BD's Technology Leadership Development program, part of a broader initiative to provide a pipeline of talent for the company. He is a member of numerous professional organizations and engages in charitable and philanthropic efforts for the Juvenile Diabetes Research Foundation and Princeton University and is an advisor to the Whiting School of Engineering at Johns Hopkins as well as to the Chem Bio Engineering departments at Hopkins and Princeton.
James Hemp, Ph.D.
Dr. James Hemp is an Agouron Scholar at the California Institute of Technology in the Division of Geological and Planetary Sciences, and an Adjunct Professor at the University of Utah in the Division of Gastroenterology. His research focuses on microbial diversity, physiology, ecology, and evolution in environmental and host-associated systems. James received a BS in Physics from the University of Minnesota and a PhD in Biophysics and Computational Biology from the University of Illinois at Urbana-Champaign.
Jonathan Kabakoff is a Senior Principal - Science and Technology at Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. In his role, Mr. Kabakoff is responsible for strategic venture capital investments, business development, and tenant underwriting in Alexandria’s San Diego and Seattle cluster locations through the company’s strategic venture investment arm, Alexandria Venture Investments. While at Alexandria, he has led venture capital investments in more than 30 life science companies primarily in the areas of therapeutics, diagnostics, and life science research tools. Mr. Kabakoff represents Alexandria as a Board Observer of Metacrine, Inc. He is on the board of SparkBio, an invitation-only networking group that brings together up-and-coming life science professionals in San Diego, and is a member of the Biocom Capital Development Committee. Prior to joining Alexandria, Mr. Kabakoff held research positions at Gen-Probe and Genoptix, where he gained experience in biochemistry, assay development, and molecular diagnostics. He also held a neuroscience research position at the Burnham Institute for Medical Research. Jonathan holds a BS in Chemistry from Stanford University.
Isaac Kohane, MD, Ph.D.
Dr. Isaac Kohane co-directs the Center for Biomedical Informatics at Harvard Medical School. He applies computational techniques, whole genome analysis, and functional genomics to study human diseases through the developmental lens, and particularly through the use of animal model systems. Dr. Kohane has led the use of whole healthcare systems, notably in the i2b2 project, as “living laboratories” to drive discovery research in disease genomics (with a focus on autism) and pharmacovigilance (including providing evidence for the cardiovascular risk of hypoglycemic agents which ultimately contributed to “black box”ing by the FDA) and comparative effectiveness with software and methods adopted in over 84 academic health centers internationally. Dr. Kohane has published over 200 papers in the medical literature and authored a widely used book on Microarrays for an Integrative Genomics. He has been elected to multiple honor societies including the American Society for Clinical Investigation, the American College of Medical Informatics, and the Institute of Medicine. He leads a doctoral program in genomics and bioinformatics within the Division of Medical Science at Harvard University. He is also an occasionally practicing pediatric endocrinologist.
Laura A. Pace, MD, Ph.D.
Dr. Laura Pace is an Assistant Professor at the University of Utah within the Division of Gastroenterology. Dr. Pace’s clinical interests primarily concern diseases affecting the small intestine and systemic diseases with gastrointestinal manifestations. Her research integrates genomics and metabolomics with microbial activity measurements to delineate the human and microbial components underlying complex disease states affecting the gastrointestinal tract. Dr. Pace will be joining the Rare Disease Clinic at the University of Utah. This unique clinic integrates the expertise of Gastroenterologists, Neurologists, Rheumatologists and Geneticists to diagnose and manage individuals with complex disease processes. She received her Ph.D. in Neuroscience in 2007 and her M.D. in 2010. Dr. Pace completed her Gastroenterology Fellowship at the University of Utah and University of California San Diego as part of the American Board of Internal Medicine Physician Scientist Training Program.
Ming Jack Po, MD, Ph.D.
Jack Po is a product manager at Google working on health search. His work focuses on helping consumers better understand health information, and extracting health related insights from healthcare and consumer data. Jack is heavily involved in healthcare entrepreneurship and has previously served as an Entrepreneur-In-Residence at CorIdea, a medical device incubator, and continues to serve as an independent board member of several healthcare and IT startups. He received his BS in BME and MA in Mathematics from Johns Hopkins University, and his MD and PhD from Columbia University.
Lori Pressman has been an independent deal maker, license negotiator, business development and technology transfer strategic advisor since 2000. Recent assignments include licensing biotech and oncology inventions for academic medical centers. She was a Director at Harris & Harris from 2002-2012, an advisor for Axsun Technologies prior to its acquisition by Volcano, and Assistant Director with the MIT Technology Licensing Office. She is a member of the grant review committee at the MIT Deshpande Center for Technological Innovation and frequent coach of entrepreneurs and students studying entrepreneurship and business development. She is on the Association of University Technology Managers (AUTM) Public Policy Committee. She is an inventor on a half dozen medical device patents and earned the SB, Physics from MIT and the MSEE from the Columbia School of Engineering.
Katharina Ribbeck, Ph.D.
Prof. Katharina Ribbeck is the Eugene Bell Career Development Professor of Tissue Engineering at MIT. Her work focuses on the basic mechanisms by which mucus barriers exclude, or allow passage of different molecules and pathogens, and the mechanisms pathogens have evolved to penetrate mucus barriers. She hopes to provide the foundation for a theoretical framework that captures general principles governing selectivity in mucus and potentially other biological hydrogels including the extracellular matrix and bacterial biofilms. Prof. Ribbeck obtained her BS and her Ph.D. in Biology from the University of Heidelberg, Germany. She continued her postdoctoral research at the European Molecular Biology Laboratory, Heidelberg, Germany, and the Department of Systems Biology, Harvard Medical School. Prof. Ribbeck established her independent research group as a Bauer Fellow at the FAS Center for Systems Biology, Harvard University, in 2007 and joined the Department of Biological Engineering at MIT as an Assistant Professor in 2010.
Naureen A. Shaikh, MD
Dr. Naureen Shaikh, FAAFP, started Mobile Medical Team International with partners in Tanzania, building a hospital from start to finish in six months in 2006. Dr. Shaikh is a global leader in human centered design and a regular participant at the Skoll World Forum, Singularity University and the AAFP Global Health Forum. From her start as a child in a large immigrant family in rural Michigan, Dr. Shaikh went on to obtain triple honors degrees at the University of Michigan, a Medical Degree at Rush, and ABFM at Tufts University. She was an awarded teacher at Tufts, Harvard and Stanford Schools of Medicine. She received the Doctor of the Year award in 2013 from the California Academy of Family Physicians. Her academic and research publications span three decades. Dr. Shaikh was the Department Chair of Family Medicine for Marin General Hospital. Naureen BOD service include an FQHC, IPA and ACO. She has created innovative and sustainable US healthcare programs and a global health portal in partnership with Facebook's Internet.org currently in 46 countries and growing.
Larry Smarr, Ph.D.
Dr. Larry Smarr is the founding Director of the California Institute for Telecommunications and Information Technology (Calit2), a UC San Diego/UC Irvine partnership. He holds the Harry E. Gruber Professorship in Computer Science and Engineering at UC San Diego's Jacobs School. At Calit2, Dr. Smarr continues to drive major developments in information infrastructure, including the Internet, Web, scientific visualization, virtual reality, and global telepresence, which he began during his previous 15 years as founding Director of the National Center for Supercomputing Applications. He is a member of the National Academy of Engineering, as well as a Fellow of the American Physical Society and the American Academy of Arts and Sciences. In 2006 he received the IEEE Computer Society Tsutomu Kanai Award for his lifetime achievements in distributed computing systems and in 2014 the Golden Goose Award. He served for 8 years he was a member of the NIH Advisory Committee to the NIH Director, serving 3 directors. He is currently the Principal Investigator on the NSF Pacific Research Platform grant.
Lee Stein, J.D.
Mr. Stein is Chairman and founder, Prize Capital, LLC and Chairman and founder, Virutal Group, LLC. Mr. Stein brings many years of experience as a business executive and entrepreneur to his current activities as a business-minded environmentalist. He is credited as a co-inventor of e-mail messaging payment systems, and in 1994, he co-patented what The Economist magazine described as the world’s first Internet-banking (payment) system. The patents issued were subsequently acquired by eBay. In 2000 he formed Virtual Group, LLC, a private holding company focused on early-stage technologies. In 2006, Lee formed Prize Capital, LLC to support the X Prize Foundation and to fund global competitions aimed at discovering innovative solutions in the areas of energy and the environment. Formed to attract investment capital for early-stage innovators, the partnership is based on a model that integrates investment concepts and international prizes, and for which Lee has filed patent applications. Since its inception, Prize Capital has broadened its focus to include other for-profit opportunities that recognize the value of natural capital. Prize Capital envisions using Venture Philanthropy to create sustainable financing instruments that will value healthy ecosystems, and the benefits they provide, as an asset in both developed and developing nations.
Blake L. Stevens, Ph.D.
Dr. Blake Stevens has worked as both an entrepreneur and a venture investor. He currently serves as Vice President and Senior Associate at Harris & Harris Group, Inc., a New York City-based early-stage venture capital firm. At Harris & Harris Group, Dr. Stevens specializes in working with its earliest stage companies, including acting as COO of TARA Biosystems, Inc., and a founder of Interome, Inc. He also sits on the Board of Directors of Promuc, Inc.; Interome, Inc.; Synglyco, Inc.; and is a former member of the Board of Directors of TARA. Prior to joining Harris & Harris Group, Dr. Stevens was the seventh employee at HZO, Inc., a start-up focused on protecting electronics from environmental hazards. While at HZO he led its R&D, commercialization and technical business development efforts, helping grow the company to over 70 employees and its first significant revenue. Dr. Stevens also built and managed HZO’s intellectual property system, growing their patent portfolio from 3 to over 60 patents. He graduated from Northwestern University with a Ph.D. in Materials Science & Engineering and received a Certificate in Management for Scientists and Engineers from the Kellogg Business School. Prior to Northwestern, Dr. Stevens earned a B.Sc. at Cornell University in Materials Science & Engineering with a minor in Engineering Management.
Mr. Taylor is a Venture Partner at Digitalis, an early-stage venture capital fund focused on human health. Digitalis invests in science-backed, technology-enabled solutions to complex problems. Its investments include Second Genome, a company that brings microbiome science to the discovery and development of new therapeutics. Previously Mr. Taylor was the Head of New Ventures at Taylor Farms, the world’s largest processor of fresh-cut fruits and vegetables. During this time Mr. Taylor led the creation and investment activity of Taylor Ventures, which invests in early-stage food and ag technology companies. Mr. Taylor received his BA from Stanford University and MBA from Harvard Business School.
John Q. Walker, Ph.D.
Dr. John Walker is the CTO of Muses Labs and has led the development of Muses Labs’ clinical Precision Medicine platform and personalized disease protocols. Previously he led pioneering software efforts in local-area networks (LANs), wireless LANs (“Wi-Fi”), high-speed networking, and voice-over-IP (VoIP). His invention of “Walker’s Algorithm” has been fundamental to data visualization in fields involving hierarchical relationships. He co-founded Ganymede Software, which developed products to measure computer network performance. Dr. Walker also co-founded Zenph Sound Innovations, where software created nuanced data descriptions for understanding precisely how people perform. Walker’s career began at IBM. He was profiled in the February 2011 issue of IEEE Spectrum journal. He received his Ph.D. in computer science from UNC Chapel Hill and holds seven patents.
E. Robert Wassman, M.D.
Dr. Bob Wassman is the Chief Medical Officer of Lineagen, Inc. a Salt Lake City based company focused on genetic diagnostic services for individuals with ASD or other conditions of childhood development. He has pioneered the introduction of genetic testing and personalized medicine for over 30 years. Prior to joining Lineagen he held numerous executive positions in the field of genetic testing including CMO at Genzyme Genetics, where he led new product evaluation, and was responsible for clinical services and genetic counseling. He co-founded and was CMO at Good Start Genetics, and also held the CMO role for Rosetta Genomics, Generation Health, Helicos Biosciences, Celula, and Alfigen. His focus has been on the translation and delivery of cutting-edge diagnostic technology to clinical service in the areas of reproductive medicine, rare cell diagnostics, and Next Generation DNA sequencing. He is a graduate of Yale University and Albany Medical College and Board Certified in Pediatrics and Medical Genetics.
Peter White, Ph.D.
Dr. Peter White is a principal investigator in the Center for Microbial Pathogenesis at The Research Institute at Nationwide Children’s Hospital and an Assistant Professor of Pediatrics at The Ohio State University. He is Director of the Biomedical Genomics Core, a nationally recognized microarray and next-generation sequencing facility assisting numerous investigators in the design, production and analysis of genomics data. He is also Director of Molecular Bioinformatics, serving on the Research Computing Executive Governance Committee and the Data and Analytics Strategy Executive Committee. Dr. White has established multiple genomics initiatives as part of Nationwide Children's strategic goal to develop a cutting edge genomic medicine program. As developer and inventor of the balanced parallelization strategy for human genome analysis (named “Churchill”), Dr. White is a co-founder of GenomeNext LLC. Dr. White’s research program focuses on developing high performance computing solutions for "big data", utilizing disruptive technologies to rapidly analyze and interpret genomic data sets. Through genomic analysis of individuals, families and populations, his team is discovering genetic variation associated with diseases such as congenital heart defects, autism spectrum disorders and rare genetic diseases. Dr. White received his Ph.D. in Molecular Biology from the University of Cambridge, England and completed his postdoctoral training in the Department of Genetics at The University of Pennsylvania, Philadelphia. He has over 15 years of experience in the field of genomics and computational biology, is the recipient of multiple awards from the National Institutes of Health and has authored over 50 peer reviewed publications.
Thomas Wilckens, Ph.D.
Dr. Thomas Wilckens is a medical doctor and a serial entrepreneur. He serves as the CEO of InnVentis Ltd., with a focus on the convergence of multi-omics technologies with real-world clinical data and machine learning to enable precision medicine. The InnVentis technology platform combines data of unprecedented quality and depth with cutting-edge algorithms to create actionable insights such as cost-efficient sourcing of extremely high quality *omics analytics and clinical analytics, proprietary knowledge in machine learning and algorithm development, and stringent control of sample and data collection with proprietary standard operation procedures. Dr. Wilckens is also the founder of the LinkedIn group Precision Medicine & Big Data. Prior to InnVentis, he was an associate at deep innovation GmbH, a boutique consultancy and spin-off of Vodafone Group R&D Germany. In 1998 founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. He obtained his MD at the Ludwig-Maximilian University in Munich and started his research career as a scholar of the Max-Planck Society and the Max-Kade Foundation in New York. He held several post-doctorate positions at leading academic institutions before becoming an entrepreneur.